Literature DB >> 16825687

Dietary glycemic index and liver steatosis.

Silvia Valtueña1, Nicoletta Pellegrini, Diego Ardigò, Daniele Del Rio, Filippo Numeroso, Francesca Scazzina, Lucilla Monti, Ivana Zavaroni, Furio Brighenti.   

Abstract

BACKGROUND: Insulin resistance (IR) and liver steatosis (LS) are interlinked metabolic derangements whose prevalence is rapidly increasing, but the effect of dietary carbohydrate quality on LS is unknown.
OBJECTIVE: The objective was to describe the relation of IR and LS to total carbohydrate, total dietary fiber, and the glycemic index (GI) and glycemic load of the diet.
DESIGN: The study was a cross-sectional evaluation of 247 apparently healthy subjects who had no evidence of viral, toxic, or autoimmune hepatitis and who were unselected for alcohol intake. The homeostasis model assessment index was used as a surrogate measure of IR, and a liver echography was used as a proxy for LS grading. Dietary data were collected by using 3-d food records. Total carbohydrate intake, total dietary fiber, GI, and glycemic load were calculated by using a semiquantitative food-frequency questionnaire concerning the dietary sources of carbohydrates.
RESULTS: The prevalence of high-grade LS (HG-LS) increased significantly across quartiles of dietary GI (P for trend < 0.034): HG-LS in the 4th quartile (high GI) was twice that in the first 3 quartiles (low to medium GIs), whereas no relation was observed with total carbohydrates, total dietary fiber, or glycemic load. In insulin-sensitive subjects (first 3 quartiles of homeostasis model assessment index of IR), the prevalence of HG-LS did not differ significantly between GI groups, but, in insulin-resistant subjects (4th quartile of homeostasis model assessment index of IR), it was twice as high in those with high GI as in those with low to medium GIs (P = 0.005).
CONCLUSIONS: High-GI dietary habits are associated with HG-LS, particularly in insulin-resistant subjects. Dietary advice on the quality of carbohydrate sources therefore may be a complementary tool for preventing or treating LS of metabolic origin.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16825687     DOI: 10.1093/ajcn/84.1.136

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  32 in total

1.  Methodological challenges in the application of the glycemic index in epidemiological studies using data from the European Prospective Investigation into Cancer and Nutrition.

Authors:  Marit M E van Bakel; Nadia Slimani; Edith J M Feskens; Huaidong Du; Joline W J Beulens; Yvonne T van der Schouw; Furio Brighenti; Jytte Halkjaer; Anne E Cust; Pietro Ferrari; Jennie Brand-Miller; H Bas Bueno-de-Mesquita; Petra Peeters; Eva Ardanaz; Miren Dorronsoro; Francesca L Crowe; Sheila Bingham; Sabine Rohrmann; Heiner Boeing; Ingegerd Johansson; Jonas Manjer; Anne Tjonneland; Kim Overvad; Eiliv Lund; Guri Skeie; Amalia Mattiello; Simonetta Salvini; Françoise Clavel-Chapelon; Rudolf Kaaks
Journal:  J Nutr       Date:  2009-01-21       Impact factor: 4.798

Review 2.  Optimal dietary approaches for prevention of type 2 diabetes: a life-course perspective.

Authors:  A E Buyken; P Mitchell; A Ceriello; J Brand-Miller
Journal:  Diabetologia       Date:  2010-01-05       Impact factor: 10.122

3.  Long-term effects of dietary glycemic index on adiposity, energy metabolism, and physical activity in mice.

Authors:  Kelly B Scribner; Dorota B Pawlak; Cristin M Aubin; Joseph A Majzoub; David S Ludwig
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-09-09       Impact factor: 4.310

Review 4.  Practical management of the increasing burden of non-alcoholic fatty liver disease.

Authors:  Angelina Mouralidarane; Ching-I Lin; Narin Suleyman; Junpei Soeda; Jude A Oben
Journal:  Frontline Gastroenterol       Date:  2010-09-23

5.  Associations between dietary factors and markers of NAFLD in a general Dutch adult population.

Authors:  A Rietman; D Sluik; E J M Feskens; F J Kok; M Mensink
Journal:  Eur J Clin Nutr       Date:  2017-09-13       Impact factor: 4.016

6.  Beneficial effect of a weight-stable, low-fat/low-saturated fat/low-glycaemic index diet to reduce liver fat in older subjects.

Authors:  Kristina M Utzschneider; Jennifer L Bayer-Carter; Matthew D Arbuckle; Jaime M Tidwell; Todd L Richards; Suzanne Craft
Journal:  Br J Nutr       Date:  2012-07-31       Impact factor: 3.718

7.  Antisocial behavioral syndromes and past-year physical health among adults in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Risë B Goldstein; Deborah A Dawson; S Patricia Chou; W June Ruan; Tulshi D Saha; Roger P Pickering; Frederick S Stinson; Bridget F Grant
Journal:  J Clin Psychiatry       Date:  2008-03       Impact factor: 4.384

Review 8.  Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease.

Authors:  Kristina Blaslov; Tomislav Bulum; Karin Zibar; Lea Duvnjak
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

9.  A low-glycemic-load versus low-fat diet in the treatment of fatty liver in obese children.

Authors:  Marta Ramon-Krauel; Sandra L Salsberg; Cara B Ebbeling; Stephan D Voss; Robert V Mulkern; Margaret M Apura; Emily A Cooke; Karen Sarao; Maureen M Jonas; David S Ludwig
Journal:  Child Obes       Date:  2013-05-24       Impact factor: 2.992

10.  Glycemic index, glycemic load, dietary carbohydrate, and dietary fiber intake and risk of liver and biliary tract cancers in Western Europeans.

Authors:  V Fedirko; A Lukanova; C Bamia; A Trichopolou; E Trepo; U Nöthlings; S Schlesinger; K Aleksandrova; P Boffetta; A Tjønneland; N F Johnsen; K Overvad; G Fagherazzi; A Racine; M C Boutron-Ruault; V Grote; R Kaaks; H Boeing; A Naska; G Adarakis; E Valanou; D Palli; S Sieri; R Tumino; P Vineis; S Panico; H B As Bueno-de-Mesquita; P D Siersema; P H Peeters; E Weiderpass; G Skeie; D Engeset; J R Quirós; R Zamora-Ros; M J Sánchez; P Amiano; J M Huerta; A Barricarte; D Johansen; B Lindkvist; M Sund; M Werner; F Crowe; K T Khaw; P Ferrari; I Romieu; S C Chuang; E Riboli; M Jenab
Journal:  Ann Oncol       Date:  2012-11-02       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.